WO2013169350A1 - Biosynthetic pathways, recombinant cells, and methods - Google Patents
Biosynthetic pathways, recombinant cells, and methods Download PDFInfo
- Publication number
- WO2013169350A1 WO2013169350A1 PCT/US2013/030719 US2013030719W WO2013169350A1 WO 2013169350 A1 WO2013169350 A1 WO 2013169350A1 US 2013030719 W US2013030719 W US 2013030719W WO 2013169350 A1 WO2013169350 A1 WO 2013169350A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- wild
- recombinant
- type control
- bacterial cell
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 51
- 230000006696 biosynthetic metabolic pathway Effects 0.000 title description 15
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims abstract description 133
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 claims abstract description 63
- UAXOELSVPTZZQG-UHFFFAOYSA-N tiglic acid Natural products CC(C)=C(C)C(O)=O UAXOELSVPTZZQG-UHFFFAOYSA-N 0.000 claims abstract description 63
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 44
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 claims description 51
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 claims description 51
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 47
- 230000000694 effects Effects 0.000 claims description 47
- 108090000489 Carboxy-Lyases Proteins 0.000 claims description 44
- 102000004031 Carboxy-Lyases Human genes 0.000 claims description 44
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 31
- 230000001580 bacterial effect Effects 0.000 claims description 31
- 229910052799 carbon Inorganic materials 0.000 claims description 30
- 239000004473 Threonine Substances 0.000 claims description 29
- 238000006243 chemical reaction Methods 0.000 claims description 29
- 229960002898 threonine Drugs 0.000 claims description 29
- TYEYBOSBBBHJIV-UHFFFAOYSA-M 2-oxobutanoate Chemical compound CCC(=O)C([O-])=O TYEYBOSBBBHJIV-UHFFFAOYSA-M 0.000 claims description 27
- BYGQBDHUGHBGMD-UHFFFAOYSA-N 2-methylbutanal Chemical compound CCC(C)C=O BYGQBDHUGHBGMD-UHFFFAOYSA-N 0.000 claims description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 24
- 150000004715 keto acids Chemical class 0.000 claims description 21
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 19
- 239000008103 glucose Substances 0.000 claims description 19
- XNIHZNNZJHYHLC-UHFFFAOYSA-N 2-oxohexanoic acid Chemical compound CCCCC(=O)C(O)=O XNIHZNNZJHYHLC-UHFFFAOYSA-N 0.000 claims description 16
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 15
- JVQYSWDUAOAHFM-BYPYZUCNSA-N (S)-3-methyl-2-oxovaleric acid Chemical compound CC[C@H](C)C(=O)C(O)=O JVQYSWDUAOAHFM-BYPYZUCNSA-N 0.000 claims description 14
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 14
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 14
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 14
- 108091033319 polynucleotide Proteins 0.000 claims description 14
- 102000040430 polynucleotide Human genes 0.000 claims description 14
- 239000002157 polynucleotide Substances 0.000 claims description 14
- 229920001184 polypeptide Polymers 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 239000001893 (2R)-2-methylbutanal Substances 0.000 claims description 12
- 241000588724 Escherichia coli Species 0.000 claims description 12
- 239000000758 substrate Substances 0.000 claims description 12
- KDVFRMMRZOCFLS-UHFFFAOYSA-M 2-oxopentanoate Chemical compound CCCC(=O)C([O-])=O KDVFRMMRZOCFLS-UHFFFAOYSA-M 0.000 claims description 11
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 11
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 11
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N pentanal Chemical compound CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 claims description 11
- 230000000813 microbial effect Effects 0.000 claims description 10
- 230000002538 fungal effect Effects 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 7
- 229930006000 Sucrose Natural products 0.000 claims description 7
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 7
- 239000001913 cellulose Substances 0.000 claims description 7
- 229920002678 cellulose Polymers 0.000 claims description 7
- 239000005720 sucrose Substances 0.000 claims description 7
- 241000194035 Lactococcus lactis Species 0.000 claims description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 6
- 235000014897 Streptococcus lactis Nutrition 0.000 claims description 6
- MEUAVGJWGDPTLF-UHFFFAOYSA-N 4-(5-benzenesulfonylamino-1-methyl-1h-benzoimidazol-2-ylmethyl)-benzamidine Chemical compound N=1C2=CC(NS(=O)(=O)C=3C=CC=CC=3)=CC=C2N(C)C=1CC1=CC=C(C(N)=N)C=C1 MEUAVGJWGDPTLF-UHFFFAOYSA-N 0.000 claims description 5
- 241000192700 Cyanobacteria Species 0.000 claims description 4
- 241000192125 Firmicutes Species 0.000 claims description 4
- 241000193453 [Clostridium] cellulolyticum Species 0.000 claims description 4
- 230000001461 cytolytic effect Effects 0.000 claims description 4
- 230000000243 photosynthetic effect Effects 0.000 claims description 4
- 241001112741 Bacillaceae Species 0.000 claims description 3
- 244000063299 Bacillus subtilis Species 0.000 claims description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 3
- 241000222122 Candida albicans Species 0.000 claims description 3
- 241001430149 Clostridiaceae Species 0.000 claims description 3
- 241000222175 Diutina rugosa Species 0.000 claims description 3
- 241000588921 Enterobacteriaceae Species 0.000 claims description 3
- 241000589776 Pseudomonas putida Species 0.000 claims description 3
- 241000235344 Saccharomycetaceae Species 0.000 claims description 3
- 241000194018 Streptococcaceae Species 0.000 claims description 3
- 229940095731 candida albicans Drugs 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 description 64
- 102000004169 proteins and genes Human genes 0.000 description 63
- 238000004519 manufacturing process Methods 0.000 description 36
- 102000004190 Enzymes Human genes 0.000 description 28
- 108090000790 Enzymes Proteins 0.000 description 28
- 108010072869 indolepyruvate decarboxylase Proteins 0.000 description 27
- 239000000126 substance Substances 0.000 description 18
- 230000001851 biosynthetic effect Effects 0.000 description 17
- 238000000855 fermentation Methods 0.000 description 16
- 230000004151 fermentation Effects 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 16
- 101100490769 Rattus norvegicus Aldh1a1 gene Proteins 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 12
- 238000006467 substitution reaction Methods 0.000 description 12
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 11
- 230000003197 catalytic effect Effects 0.000 description 11
- 230000037361 pathway Effects 0.000 description 11
- 101710088194 Dehydrogenase Proteins 0.000 description 9
- 108050004645 Indole-3-pyruvate decarboxylases Proteins 0.000 description 9
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 9
- 150000001299 aldehydes Chemical class 0.000 description 9
- 241001508395 Burkholderia sp. Species 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 239000006227 byproduct Substances 0.000 description 6
- 238000007824 enzymatic assay Methods 0.000 description 6
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 6
- 230000037353 metabolic pathway Effects 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 229930027917 kanamycin Natural products 0.000 description 5
- 229960000318 kanamycin Drugs 0.000 description 5
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 5
- 229930182823 kanamycin A Natural products 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 5
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 5
- 241000894007 species Species 0.000 description 5
- YGHRJJRRZDOVPD-UHFFFAOYSA-N 3-methylbutanal Chemical compound CC(C)CC=O YGHRJJRRZDOVPD-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108010084086 Succinate-Semialdehyde Dehydrogenase Proteins 0.000 description 4
- 102100023673 Succinate-semialdehyde dehydrogenase, mitochondrial Human genes 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229960000310 isoleucine Drugs 0.000 description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- -1 shown in FIG. IB Chemical compound 0.000 description 4
- 101710111819 2,5-dioxopentanoate dehydrogenase Proteins 0.000 description 3
- VUQLHQFKACOHNZ-UHFFFAOYSA-N 2-Aceto-2-hydroxybutanoate Chemical compound CCC(O)(C(C)=O)C(O)=O VUQLHQFKACOHNZ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000006114 decarboxylation reaction Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- WQVJUBFKFCDYDQ-BBWFWOEESA-N leubethanol Natural products C1=C(C)C=C2[C@H]([C@H](CCC=C(C)C)C)CC[C@@H](C)C2=C1O WQVJUBFKFCDYDQ-BBWFWOEESA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229960000268 spectinomycin Drugs 0.000 description 3
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 3
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 2
- QHKABHOOEWYVLI-UHFFFAOYSA-N 3-methyl-2-oxobutanoic acid Chemical compound CC(C)C(=O)C(O)=O QHKABHOOEWYVLI-UHFFFAOYSA-N 0.000 description 2
- 101710102786 ATP-dependent leucine adenylase Proteins 0.000 description 2
- 101000782236 Bothrops leucurus Thrombin-like enzyme leucurobin Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108700035559 EC 1.2.1.16 Proteins 0.000 description 2
- 108010055471 Phenylacetaldehyde dehydrogenase Proteins 0.000 description 2
- 108010048866 Succinate-Semialdehyde Dehydrogenase (NADP+) Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- IAQRGUVFOMOMEM-UHFFFAOYSA-N but-2-ene Chemical compound CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000010779 crude oil Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000012224 gene deletion Methods 0.000 description 2
- 101150095957 ilvA gene Proteins 0.000 description 2
- 230000037041 intracellular level Effects 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 101150025049 leuB gene Proteins 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 101150117659 rhtA gene Proteins 0.000 description 2
- 239000007320 rich medium Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 101150072448 thrB gene Proteins 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- PKAUICCNAWQPAU-UHFFFAOYSA-N 2-(4-chloro-2-methylphenoxy)acetic acid;n-methylmethanamine Chemical compound CNC.CC1=CC(Cl)=CC=C1OCC(O)=O PKAUICCNAWQPAU-UHFFFAOYSA-N 0.000 description 1
- 108010048295 2-isopropylmalate synthase Proteins 0.000 description 1
- 108010028984 3-isopropylmalate dehydratase Proteins 0.000 description 1
- 108010039636 3-isopropylmalate dehydrogenase Proteins 0.000 description 1
- BKAJNAXTPSGJCU-UHFFFAOYSA-N 4-methyl-2-oxopentanoic acid Chemical compound CC(C)CC(=O)C(O)=O BKAJNAXTPSGJCU-UHFFFAOYSA-N 0.000 description 1
- 102100027278 4-trimethylaminobutyraldehyde dehydrogenase Human genes 0.000 description 1
- 108010016173 6-oxohexanoate dehydrogenase Proteins 0.000 description 1
- 101710124383 Alcohol dehydrogenase YqhD Proteins 0.000 description 1
- 108010065763 Aminobutyraldehyde dehydrogenase Proteins 0.000 description 1
- 241000589938 Azospirillum brasilense Species 0.000 description 1
- 101000742087 Bacillus subtilis (strain 168) ATP-dependent threonine adenylase Proteins 0.000 description 1
- 102100023006 Basic leucine zipper transcriptional factor ATF-like 2 Human genes 0.000 description 1
- 241001453380 Burkholderia Species 0.000 description 1
- 241001646647 Burkholderia ambifaria Species 0.000 description 1
- 241000417232 Burkholderia ambifaria AMMD Species 0.000 description 1
- 241000912817 Burkholderia ambifaria IOP40-10 Species 0.000 description 1
- 241000933166 Burkholderia ambifaria MC40-6 Species 0.000 description 1
- 241000912818 Burkholderia ambifaria MEX-5 Species 0.000 description 1
- 241000371430 Burkholderia cenocepacia Species 0.000 description 1
- 241000312517 Burkholderia cenocepacia AU 1054 Species 0.000 description 1
- 241001607436 Burkholderia cenocepacia J2315 Species 0.000 description 1
- 241001040392 Burkholderia cenocepacia PC184 Species 0.000 description 1
- 241001646389 Burkholderia dolosa Species 0.000 description 1
- 241000871300 Burkholderia gladioli BSR3 Species 0.000 description 1
- 241000793266 Burkholderia glumae BGR1 Species 0.000 description 1
- 241000902885 Burkholderia multivorans ATCC 17616 Species 0.000 description 1
- 241000690802 Burkholderia multivorans CGD1 Species 0.000 description 1
- 241000690800 Burkholderia multivorans CGD2M Species 0.000 description 1
- 241000394958 Burkholderia ubonensis Bu Species 0.000 description 1
- 101100327819 Caenorhabditis elegans chl-1 gene Proteins 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 101001131614 Escherichia coli (strain K12) NADP/NAD-dependent aldehyde dehydrogenase PuuC Proteins 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101000903615 Homo sapiens Basic leucine zipper transcriptional factor ATF-like 2 Proteins 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- 101100123410 Methanosarcina acetivorans (strain ATCC 35395 / DSM 2834 / JCM 12185 / C2A) hacA gene Proteins 0.000 description 1
- 101100123415 Methanosarcina acetivorans (strain ATCC 35395 / DSM 2834 / JCM 12185 / C2A) hacB1 gene Proteins 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 241000912820 Paraburkholderia graminis C4D1M Species 0.000 description 1
- 241000838183 Paraburkholderia phymatum STM815 Species 0.000 description 1
- 241000933512 Paraburkholderia phytofirmans PsJN Species 0.000 description 1
- 241000706409 Paraburkholderia rhizoxinica HKI 454 Species 0.000 description 1
- 241000097438 Paraburkholderia xenovorans LB400 Species 0.000 description 1
- 101710125971 Putative aldehyde dehydrogenase Proteins 0.000 description 1
- 101100055268 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ALD3 gene Proteins 0.000 description 1
- 101100055273 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ALD5 gene Proteins 0.000 description 1
- 101100055274 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ALD6 gene Proteins 0.000 description 1
- 241001624367 Salmonella bongori NCTC 12419 Species 0.000 description 1
- 241000607356 Salmonella enterica subsp. arizonae Species 0.000 description 1
- 241000789939 Salmonella enterica subsp. enterica serovar Agona str. SL483 Species 0.000 description 1
- 241001617476 Salmonella enterica subsp. enterica serovar Choleraesuis str. SC-B67 Species 0.000 description 1
- 241000458513 Salmonella enterica subsp. enterica serovar Gallinarum str. 287/91 Species 0.000 description 1
- 241001153359 Salmonella enterica subsp. enterica serovar Hadar str. RI_05P066 Species 0.000 description 1
- 241000789942 Salmonella enterica subsp. enterica serovar Heidelberg str. SL486 Species 0.000 description 1
- 241001428204 Salmonella enterica subsp. enterica serovar Javiana Species 0.000 description 1
- 241000789507 Salmonella enterica subsp. enterica serovar Kentucky str. CDC 191 Species 0.000 description 1
- 241001210244 Salmonella enterica subsp. enterica serovar Montevideo str. 315996572 Species 0.000 description 1
- 241001175683 Salmonella enterica subsp. enterica serovar Paratyphi A str. ATCC 9150 Species 0.000 description 1
- 241000242340 Salmonella enterica subsp. enterica serovar Paratyphi B str. SPB7 Species 0.000 description 1
- 241001551912 Salmonella enterica subsp. enterica serovar Paratyphi C str. RKS4594 Species 0.000 description 1
- 241000789943 Salmonella enterica subsp. enterica serovar Schwarzengrund str. SL480 Species 0.000 description 1
- 241001204776 Salmonella enterica subsp. enterica serovar Tennessee str. CDC07-0191 Species 0.000 description 1
- 241000225553 Salmonella enterica subsp. enterica serovar Typhi str. CT18 Species 0.000 description 1
- 241000627923 Salmonella enterica subsp. enterica serovar Typhi str. E98-0664 Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000405383 Salmonella enterica subsp. enterica serovar Typhimurium str. LT2 Species 0.000 description 1
- 241001607429 Salmonella enterica subsp. enterica serovar Typhimurium str. SL1344 Species 0.000 description 1
- 241001153353 Salmonella enterica subsp. enterica serovar Virchow str. SL491 Species 0.000 description 1
- 241001153354 Salmonella enterica subsp. enterica serovar Weltevreden str. HI_N05-537 Species 0.000 description 1
- 101100181662 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) leuC1 gene Proteins 0.000 description 1
- 101100288829 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) leuD1 gene Proteins 0.000 description 1
- 101100125907 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) ilvC1 gene Proteins 0.000 description 1
- 101000774739 Thermus thermophilus Aspartokinase Proteins 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 102000052482 Thiamine pyrophosphate enzyme Human genes 0.000 description 1
- 108700038108 Thiamine pyrophosphate enzyme Proteins 0.000 description 1
- 241000322535 Variovorax paradoxus EPS Species 0.000 description 1
- 241000119294 Variovorax paradoxus S110 Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 101150023727 ald2 gene Proteins 0.000 description 1
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002551 biofuel Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 235000010633 broth Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XNMQEEKYCVKGBD-UHFFFAOYSA-N dimethylacetylene Natural products CC#CC XNMQEEKYCVKGBD-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 239000003502 gasoline Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 101150063051 hom gene Proteins 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 101150090497 ilvC gene Proteins 0.000 description 1
- 101150043028 ilvD gene Proteins 0.000 description 1
- 101150105723 ilvD1 gene Proteins 0.000 description 1
- 101150020087 ilvG gene Proteins 0.000 description 1
- 101150003892 ilvM gene Proteins 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 101150087199 leuA gene Proteins 0.000 description 1
- 101150081723 leuC gene Proteins 0.000 description 1
- 101150019665 leuD gene Proteins 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012269 metabolic engineering Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000002763 monocarboxylic acids Chemical class 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000012536 storage buffer Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 235000008170 thiamine pyrophosphate Nutrition 0.000 description 1
- 239000011678 thiamine pyrophosphate Substances 0.000 description 1
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 description 1
- 101150014006 thrA gene Proteins 0.000 description 1
- 101150000850 thrC gene Proteins 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- AZDRQVAHHNSJOQ-XCIZNGPVSA-N trideuterioalumane Chemical compound [2H][Al]([2H])[2H] AZDRQVAHHNSJOQ-XCIZNGPVSA-N 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 101150113187 yqhD gene Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
- C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
- C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
- C12Y102/01003—Aldehyde dehydrogenase (NAD+) (1.2.1.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/01—Carboxy-lyases (4.1.1)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/814—Enzyme separation or purification
- Y10S435/815—Enzyme separation or purification by sorption
Definitions
- This disclosure describes, in one aspect, a recombinant cell modified to exhibit increased biosynthesis of pentanoic acid compared to a wild-type control. In another aspect, this disclosure describes a recombinant cell modified to exhibit increased biosynthesis of 2- methylbutyric acid compared to a wild-type control.
- the recombinant cell can be a fungal cell or a bacterial cell. In each aspect, the recombinant cell can be photosynthetic. In each aspect, the recombinant cell can be cellulolytic.
- the increased biosynthesis of pentanoic acid can include an increase in conversion of L-aspartate to L-threonine compared to a wild-type control, an increase in conversion of L-threonine to 2-ketobutyrate compared to a wild-type control, an increase in 2-ketobutyrate elongation activity compared to a wild-type control, an increase in 2- ketovalerate elongation activity compared to a wild-type control, an increase in ketoacid decarboxylase activity compared to a wild-type control, an increase in ketoacid
- decarboxylase selectivity toward a predetermined substrate compared to a wild-type control or an increase in aldehyde dehydrogenase activity compared to a wild-type control.
- the increased biosynthesis of 2-methylbutyric acid can include an increase in conversion of L-aspartate to L-threonine compared to a wild-type control, an increase in conversion of L-threonine to 2-ketobutyrate compared to a wild-type control, an increase in conversion of 2-ketobutyrate to 2-keto-3-methylvalerate, an increase in ketoacid decarboxylase activity compared to a wild-type control, an increase in ketoacid decarboxylase selectivity toward a predetermined substrate c
- this disclosure describes a method that generally includes incubating a recombinant cell that exhibits increased biosynthesis of pentanoic acid in medium that includes a carbon source under conditions effective for the recombinant cell to produce pentanoic acid.
- the carbon source can include one or more of: glucose, pyruvate, L-aspartate, L-threonine, 2-ketobutyrate, 2-ketovalerate, 2- ketocaproate, valeraldehyde, C0 2 , cellulose, xylose, sucrose, arabinose, or glycerol.
- this disclosure describes a method that generally includes incubating a recombinant cell that exhibits increased biosynthesis of 2-methylbutyric acid in medium that includes a carbon source under conditions effective for the recombinant cell to produce 2-methylbutyric acid.
- the carbon source can include one or more of: glucose, pyruvate, L-aspartate, L-threonine, 2-ketobutyrate, 2-keto-3- methylvalerate, 2-methyl butyraldehyde, C0 2 , cellulose, xylose, sucrose, arabinose, or glycerol.
- this disclosure describes a method that generally includes introducing into a host cell a heterologous polynucleotide encoding at least one polypeptide that catalyzes conversion of a carbon source to pentanoic acid, wherein the at least one polynucleotide is operably linked to a promoter so that the modified host cell catalyzes conversion of the carbon source to pentanoic acid.
- this disclosure describes a method that generally includes introducing into a host cell a heterologous polynucleotide encoding at least one polypeptide that catalyzes conversion of a carbon source to 2-methylbutyric acid, wherein the at least one polynucleotide is operably linked to a promoter so that the modified host cell catalyzes conversion of the carbon source to 2-methylbutyric acid.
- FIG. 1 Routes for production of 2-methylbutyric acid (2MB) and pentanoic acid
- FIG. 2. Synthetic operons for (A) 2-methylbutyric acid (2MB) production. (B)
- FIG. 3 Results of fermentation experiments with different aldehyde
- FIG. 4. Results of fermentation experiments with different ketoacid decarboxylases.
- A Comparison of ketoacid decarboxylases for 2-methylbutyric acid production.
- B Comparison of ketoacid decarboxylases for production of pentanoic acid.
- FIG. 5 Results of fermentation experiments for combinations of ketoacids decarboxylases and aldehyde dehydrogenases
- A Comparison of various combinations for 2-methylbutyric acid production.
- B Comparison of various combinations for production of pentanoic acid.
- these chemicals are typically manufactured by oxidizing valeraldehyde and/or 2-methyl butyraldehyde, each of which may be made through a process in which a petroleum-based compound is reacted with synthesis gas (Dow. Product Safety
- 2-ketobutyrate is driven into synthesis of 2-keto-3-methylvalerate (KMV), the penultimate precursor to 2- methylbutyric acid.
- KMV 2-keto-3-methylvalerate
- the condensation of 2-ketobutyrate and pyruvate to 2-aceto-2- hydroxybutyrate (AHB) is catalyzed by IlvG and IlvM.
- Another two enzymes IlvC and IlvD can catalyze conversion of AHB into KMV.
- KMV is then decarboxylated by a ketoacid decarboxylase (DC) into 2-methyl butyraldehyde, which can be oxidized to 2- methylbutyric acid by an aldehyde dehydrogenase (DH).
- DC ketoacid decarboxylase
- DH aldehyde dehydrogenase
- 2-ketobutyrate can undergo two cycles of "+1" carbon chain elongation to make 2-ketocaproate (2KC).
- 2-ketoiso valerate is converted to 2-ketoisocaproate through a 3 -step chain elongation cycle catalyzed by 2-isopropylmalatesynthase (LeuA), isopropyl malate isomerase complex (LeuC, LeuD) and 3-isopropylmalate dehydrogenase (LeuB).
- DC decarboxylase
- DH dehydrogenase
- FIG. IB The biosynthetic schemes for the production of 2-methylbutyric acid (2MB) and pentanoic acid (PA) are shown in FIG. IB and FIG. 1C, respectively. All enzymes downstream of aspartate biosynthesis were overexpressed from three synthetic operons.
- One operon includes coding regions for ThrA, ThrB, and ThrC, each of which is involved in threonine synthesis, under control of the P L lacOl promoter on a low copy plasmid pIPAl carrying spectinomycin resistance marker.
- ilvA, ilvG, ilvM, ilvC, and ilvD were cloned on a low copy plasmid with a kanamycin resistance marker to get pIPA2.
- ilvA, leuA, leuB, leuC, and leuD were cloned on a low copy plasmid pIPA3 carrying a kanamycin resistance marker.
- threonine overproducer E, coli strain ATCC98082 was used in the study.
- the strain had threonine exporter gene rhtA removed to ensure high intracellular level of threonine (Zhang et al., Proc Natl Acad Sci USA 2010;107:6234-6239) as well as the alcohol dehydrogenase yqhD gene deletion to eliminate the side reactions leading to respective alcohols.
- the resultant strain is referred to hereafter as the PA1 straia
- FIG. IB and FIG. 1C were designed to include decarboxylation of ketoacids 2-keto-3-methylvalerate (FIG. IB) and 2-ketocaproate (2KC, FIG. 1C) into their respective aldehydes, followed by oxidation of the aldehydes to carboxylic acids.
- the PA1 strain was transformed with plasmids pIPAl, pIPA2, and pIPA4 to produce 2- methylbutyric acid.
- the PA1 strain was transformed with plasmids pIPAl, pIPA3, and pIPA4 to produce pentanoic acid.
- Shake flask fermentations were carried out using each recombinant strain. Using this approach, we produced 2.26 g/L of 2-methylbutyric acid and 2.12 g/L of pentanoic acid, demonstrating the feasibility of our biosynthetic approach.
- FIG. 3 A and FIG. 3B Six aldehyde dehydrogenases were selected as candidate enzymes for this study: acetaldehyde dehydrogenase AldB (Ho and Weiner, J Bacteriol 2005;187:1067-1073), 3-hydroxypropionaldehyde dehydrogenase AldH (Jo et al., Appl Microbiol Biotechnol 2008;81 :51-60), phenylacetaldehyde dehydrogenase PadA (Rodriguez-Zavala et al., Protein Sci 2006;15:1387-1396), succinate semialdehyde dehydrogenase GabD (Bartsch et al., J Bacteriol 1990;172:7035-7042), ⁇ - aminobutyraldehyde dehydrogenase YdcW (Gruez et al.
- Bacterial strains were constructed with three synthetic operons as shown in FIG. 2. All heterologous enzymes introduce into the strains were identical across the strain with the exception of the aldehyde
- Wild-type KIVD was selected as the 2-ketoacid decarboxylase for each strain.
- Shake flask fermentations were carried out at 30°C and samples were analyzed by HPLC. The fermentations were analyzed to identify the strain— and therefore the aldehyde dehydrogenase—that produced the highest quantity of desired product.
- the PA1 strain was transformed with plasmids pIPAl, pIPA2, and any one of pIPA4 to pIPA9.
- the highest titer of 2.51 g/L was achieved with AldH, while AldB, PadA, KDH ba , GabD and YdcW produced 2.31 g/L, 2.26 g/L, 0.67 g/L, 0.14 g/L and 0.23 g/L, respectively (FIG. 3 A).
- the PA1 strain was transformed with plasmids pIPAl, pIPA3, and any one of pIPA4 to pIPA9.
- ⁇ 3 ⁇ 4 & was found to be most active aldehyde dehydrogenase for producing pentanoic acid (2.25 g/L), while AldH, AldB, PadA, GabD and YdcW produced 1.76 g/L, 0.42 g/L, 2.12 g/L, 0.54 g/L, and 0.22 g/L, respectively (FIG. 3B).
- the PA1 strain was transformed with pIPAl, pIPA2, and any one of the plasmids pIPAlO to pIPA13 for 2-methylbutyric acid.
- the PA1 strain was transformed with pIPAl, pIPA3, and any one of the plasmids pIPAlO to pIPA13 for pentanoic acid synthesis.
- IPDC 2-Keto-3 -methylvalerate 0.85 ⁇ 0.18 4.13 ⁇ 0.21 4.86
- KD3 ⁇ 4a has significantly lower KM towards valeraldehyde (0.031 mM) than smaller or branched substrates like isobutyraldehyde (34.5 mM) and isovaleraldehyde (7.62 mM) but similar A; ca t values (Xiong et al., Sci Rep 2012;2). Therefore, the specificity constant (k cat /K ) of KDH b a towards valeraldehyde is 1260-fold and 308-fold higher than those toward isobutyraldehyde and isovaleraldehyde.
- Pentanoic acid and 2-methylbutyric acid are two valuable chemical intermediates in chemical industry.
- the purpose of this study was to investigate feasibility of biosynthetic approach to synthesize these chemicals.
- the heterologous enzymes involved in the pathways were overexpressed by cloning
- polynucleotides that encode the enzymes into a synthetic operon.
- the designed pathways exemplified herein include decarboxylation of ketoacids 2-keto-3 -methylvalerate and 2- ketocaproate into respective aldehydes, followed by oxidation to carboxylic acids.
- biosynthetic strategy described herein is a promising advance towards sustainable production of such platform chemicals. Moreover, since the biosynthetic pathways described herein are modifications of the host's native amino acid biosynthetic pathways, and those native biosynthetic pathways are highly conserved across species, the biosynthetic modifications described herein may be applied to the native biosynthetic pathways of a variety of additional organisms.
- the invention provides recombinant microbial cell modified to exhibit increased biosynthesis of pentanoic acid compared to a wild-type control.
- the invention provides a recombinant microbial cell modified to exhibit increased biosynthesis of 2-methylbutyric acid compared to a wild-type control.
- the wild-type control may be unable to produce pentanoic acid or 2-methylbutyric acid and, therefore, an increase in the biosynthesis of a particular product may reflect any measurable biosynthesis of that product.
- an increase in the biosynthesis of pentanoic acid or 2-methylbutyric acid can include biosynthesis sufficient for a culture of the microbial cell to accumulate pentanoic acid or 2-methylbutyric acid to a predetermine concentration.
- the predetermined concentration may be any predetermined concentration of the product suitable for a given application.
- a predetermined concentration may be, for example, a concentration of at least 0.1 g/L such as, for example, at least 0.5 g/L, at least 1.0 g/L, at least 2.0 g/L, at least 3.0 g/L, at least 4.0 g/L, at least 5.0 g/L, at least 6.0 g/L, at least 7.0 g/L, at least 8.0 g/L, at least 9.0 g/L, at least 10 g/L, at least 20 g/L, at least 50 g/L, at least 100 g/L, or at least 200 g/L.
- the recombinant cell can be, or be derived from, any suitable microbe including, for example, a prokaryotic microbe or a eukaryotic microbe.
- a prokaryotic microbe or a eukaryotic microbe.
- the term “or derived from” in connection with a microbe simply allows for the "host cell” to possess one or more genetic modifications before being modified to exhibit the indicated increased biosynthetic activity.
- the term “recombinant cell” encompasses a "host cell” that may contain nucleic acid material from more than one species before being modified to exhibit the indicated biosynthetic activity.
- the leucine and isoleucine biosynthetic pathways that are the basis for our engineered biosynthetic pathways are highly conserved across species. This conservation across species means that our pathways, exemplified in an E. coli host, may be introduced into other host cell species, if desired.
- the host cell may be selected to possess one or more natural physiological activities.
- the host cell may be photosynthetic (e.g.,
- cyanobacteria may be cellulolytic (e.g., Clostridium cellulolyticum).
- the recombinant cell may be, or be derived from, a eukaryotic microbe such as, for example, a fungal cell.
- the fungal cell may be, or be derived from, a member of the Saccharomycetaceae family such as, for example, Saccharomyces cerevisiae, Candida rugosa, or Candida albicans.
- the recombinant cell may be, or be derived from, a prokaryotic microbe such as, for example, a bacterium.
- the bacterium may be a member of the phylum Protobacteria.
- Exemplary members of the phylum Protobacteria include, for example, members of the Enterobacteriaceae family (e.g., Escherichia coli) and, for example, members of the Pseudomonaceae family (e.g.,
- the bacterium may be a member of the phylum Firmicutes.
- Exemplary members of the phylum Firmicutes include, for example, members of the Bacillaceae family (e.g., Bacillus subtilis), members of the Clostridiaceae family (e.g., Clostridium cellulolyticum) and, for example, members of the Streptococcaceae family (e.g., Lactococcus lactis).
- the bacterium may be a member of the phylum Cyanobacteria.
- the increased biosynthesis of pentanoic acid compared to a wild-type control can include an increase in elongating 2-ketobutyrate to 2-ketovalerate compared to a wild-type control, an increase in elongating 2-ketovalerate to 2-ketocaproate compared to wild-type control, increased ketoacid decarboxylase activity compared to a wild-type control, and/or increased aldehyde dehydrogenase activity compared to a wild- type control.
- the increased biosynthesis of 2-methylbutyric acid compared to a wild-type control can include increased conversion of threonine to 2- ketobutyrate compared to a wild-type control, increased conversion of 2-ketobutyrate to 2- keto-3-methylvalerate compared to a wild-type control, increased ketoacid decarboxylase activity compared to a wild-type control, and/or increased aldehyde dehydrogenase activity compared to a wild-type control.
- at least a portion of the increased ketoacid decarboxylase activity can result from modification of the ketoacid decarboxylase enzyme.
- 2-ketoacid decarboxylase of Lactococcus lactis may be modified to include at least one amino acid substitution selected from: V461A, M538A, or F542L, or an analogous substitution.
- the 2-ketoacid decarboxylase can be modified to include the V461A substitution (or an analogous substitution) in combination with either the M528A substitution (or an analogous substitution) or the V461A substitution (or an analogous substitution).
- analog refers to a related enzyme from the same or a different microbial source with similar enzymatic activity.
- analogs often show significant conservation and it is a trivial matter for a person of ordinary skill in the art to identify a suitable related analog of any given enzyme.
- an “analogous substitution” by aligning the amino acid sequence of the analog with the amino acid sequence of the reference enzyme.
- positional differences and/or amino acid residue differences may exist between the recited substitution and an analogous substitution despite conservation between the analog and the reference enzyme.
- the recombinant cell can exhibit an increase in
- IPDC indolepyruvate decarboxylase
- the recombinant cell can include a heterologous polynucleotide sequence that encodes an IPDC decarboxylase such as, for example, any one of the polypeptides reflected in any one SEQ ID NO: 1-21.
- the recombinant cell can exhibit an increase in aldehyde dehydrogenase activity.
- the increase in aldehyde dehydrogenase activity can result from expression of an aldehyde dehydrogenase enzyme.
- Exemplary aldehyde dehydrogenase enzymes include, for example, any one of the polypeptides reflected in any one of SEQ ID NO:22-55.
- the recombinant cell can include a heterologous polynucleotide sequence that encodes an aldehyde dehydrogenase such as, for example, any one of the polypeptides reflected in any one SEQ ID NO:22-55.
- the term "activity" with regard to particular enzyme refers to the ability of a polypeptide, regardless of its common name or native function, to catalyze the conversion of the enzyme's substrate to a product, regardless of whether the "activity" is less than, equal to, or greater than the native activity of the identified enzyme. Methods for measuring the biosynthetic activities of cells are routine and well known to those of ordinary skill in the art.
- the term “activity” refers to the ability of the genetically-modified cell to synthesize an identified product compound, regardless of whether the "activity" is less than, equal to, or greater than the native activity of a wild-type strain of the cell.
- an increase in catalytic activity may be expressed as an increase in k cat such as, for example, at least a two-fold increase, at least a three-fold increase, at least a four-fold increase, at least a five-fold increase, at least a six-fold increase, at least a sevenfold increase, at least an eight-fold increase, at least a nine-fold increase, at least a 10-fold increase, at least a 15 -fold increase, or at least a 20-fold increase in the k ca t value of the enzymatic conversion.
- An increase in catalytic activity also may be expressed in terms of a decrease in K m such as, for example, at least a two-fold decrease, at least a three-fold decrease, at least a four-fold decrease, at least a five-fold decrease, at least a six-fold decrease, at least a sevenfold decrease, at least an eight-fold decrease, at least a nine-fold decrease, at least a 10-fold decrease, at least a 15-fold decrease, or at least a 20-fold decrease in the K m value of the enzymatic conversion.
- a decrease in catalytic activity of an enzyme or an increase in the biosynthetic activity of a genetically-modified cell can be quantitatively measured and described as a percentage of the catalytic activity of an appropriate wild-type control.
- the catalytic activity exhibited by a genetically-modified polypeptide or the biosynthetic activity of a genetically-modified cell can be, for example, no more than 95%, no more than 90%, no more than 85%, no more than 80%, no more than 75%, no more than 70%, no more than 65%, no more than 60%, no more than 55%, no more than 50%, no more than 45%, no more than 40%, no more than 35%, no more than 30%, no more than 25%, no more than 20%, no more than 15%, no more than 10%, no more than 5%, no more than 4%>, no more than 3%, no more than 2%, no more than 1% of the activity, or 0% of the activity of a suitable wild-type control.
- a decrease in catalytic activity can be expressed as a decrease in £ cat such as, for example, at least a two-fold decrease, at least a three-fold decrease, at least a four-fold decrease, at least a five-fold decrease, at least a six-fold decrease, at least a sevenfold decrease, at least an eight-fold decrease, at least a nine-fold decrease, at least a 10-fold decrease, at least a 15-fold decrease, or at least a 20-fold decrease in the k cst value of the enzymatic conversion.
- a decrease in catalytic activity also may be expressed in terms of an increase in K m such as, for example, an increase in K m of at least two-fold, at least three-fold, at least fourfold, at least five-fold, at least six-fold, at least seven-fold, at least an eight-fold, at least nine-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 30-fold, at least 35-fold, at least 40-fold, at least 45-fold, at least 50-fold, at least 75-fold, at least 100-fold, at least 150-fold, at least 200-fold, at least 230-fold, at least 250-fold, at least 300- fold, at least 350-fold, or at least 400-fold.
- K m such as, for example, an increase in K m of at least two-fold, at least three-fold, at least fourfold, at least five-fold, at least six-fold, at least seven-fold, at least an eight-fold, at least nine-fold
- the methods includes incubating a recombinant cell as described herein in medium that includes a carbon source under conditions effective for the recombinant cell to produce pentanoic acid or 2-methylbutyric acid.
- the carbon source can include one or more of: glucose, pyruvate, L- aspartate, L-threonine, 2-ketobutyrate, 2-ketovalerate, 2-ketocaproate, or valeraldehyde.
- the carbon source can include one or more of: glucose, pyruvate, L-aspartate, L-threonine, 2-ketobutyrate, 2-keto-3 -methyl valerate, or 2-methyl butyraldehyde.
- the carbon sources for cell growth can be C0 2 , cellulose, glucose, xylose, sucrose, arabinose, glycerol, etc. as long as the related carbon assimilation pathways are introduced in the engineered microbe.
- the heterologous polynucleotide can encode a polypeptide operably linked to a promoter so that the modified cell catalyzes conversion of the carbon source to pentanoic acid.
- the carbon source can include one or more of glucose, pyruvate, L- aspartate, L-threonine, 2-ketobutyrate, 2-ketovalerate, 2-ketocaproate, or valeraldehyde.
- the heterologous polynucleotide can encode a polypeptide operably linked to a promoter so that the modified cell catalyzes conversion of the carbon source to 2-methyl butyraldehyde.
- the carbon source can include one or more of glucose, pyruvate, L-aspartate, L-threonine, 2- ketobutyrate, 2-keto-3 -methyl valerate, or 2-methyl butyraldehyde.
- the host cells for such methods can include, for example, any of the microbial species identified above with regard to the recombinant cells described herein.
- the term “and/or” means one or all of the listed elements or a combination of any two or more of the listed elements; the term “comprises” and variations thereof do not have a limiting meaning where these terms appear in the description and claims; unless otherwise specified, "a,” “an,” “the,” and “at least one” are used interchangeably and mean one or more than one; and the recitations of numerical ranges by endpoints include all numbers subsumed within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc.).
- embodiment can include a combination of compatible features described herein in connection with one or more embodiments.
- the E. coli strain used in this study was a threonine overproducer strain
- ATCC98082 which had threonine and homoserine exporter gene rhtA knocked out to ensure high intracellular level of threonine (Zhang et al., Proc Natl Acad Sci USA
- the yqhD gene deletion strain was obtained from the Keio collection (Baba et al., Mol Syst Biol 2006;2:2006.0008). It was transformed with plasmid pCP20 to remove the kanamycin resistance marker. This strain was transformed with plasmids pIPAl, pIPA2 and one of the pIPA4 to pIPA15 for production of 2-methylbutyric acid. For production of pentanoic acid, it was transformed with pIPAl, pIPA3 and any one of the pIPA4 to pIPA15.
- XL 1 -Blue and XLIO-Gold competent cells used for propagation of plasmids were from Stratagene (La Jolla, CA) while BL21 competent cells used for protein expression were from New England Biolabs (Ipswich, MA). All the restriction enzymes, QUICK LIGATION kit and PHUSION high-fidelity PCR kit were also from New England Biolabs.
- a 2x YT rich medium (16 g/L Bacto-tryptone, 10 g/L yeast extract and 5 g/L NaCl) was used to culture the E. coli strains at 37°C and 250 rpm. Antibiotics were added as needed (100 mg/L ampicillin, 25 mg/L kanamycin and 25 mg/L spectinomycin).
- AldH was purified by cloning the gene into an expression plasmid encoding an N- terminal 6x His-tag to get pIPA16. This plasmid was then transformed into E. coli strain BL21. Cells were inoculated from an overnight pre-culture at 1/300 dilution and grown at 30°C in 300 ml 2x YT rich medium containing 100 ⁇ g/L ampicillin. When the OD reached 0.6, IPTG was added to induce protein expression. Cell pellets were lysed by sonication in a buffer (pH 9.0) containing 250 mM NaCl, 2 mM DTT, 5 mM imidazole and 50 mM Tris. The enzyme was purified from crude cell lysate through Ni-NTA column
- Enzymatic assay of KDH b a consisted of 0.5 mM NAD+ and valeraldehyde in the range of 50 ⁇ to 400 ⁇ in assay buffer (50 mM NaH 2 P0 4 , pH 8.0, lmM DTT) with a total volume of 78 ⁇ . To start the reaction, 2 ⁇ , of 1 ⁇ KDH b a was added and generation of NADH was monitored at 340 nm (extinction coefficient, 6.22 mM "1 cm “1 ). A similar protocol was used for AldH with 2-Methyl butyraldehyde concentrations in the range of 1 mM to 6 mM.
- IPDC IP-binding protein
- aldehyde dehydrogenase (AldH for 2-Keto-3-methylvalerate and ⁇ 3 ⁇ 4 3 for 2-Ketocaproate) was used to oxidize aldehyde into acid while cofactor NAD+ was reduced to NADH.
- the assay mixture contained 0.5 mM NAD+, 0.1 ⁇ appropriate aldehyde dehydrogenase and corresponding 2-keto acid in the range of 1 mM to 8 mM in assay buffer (50 mM NaH 2 P0 4 , pH 6.8, 1 mM MgS04, 0.5 mM ThDP) with a total volume of 78 iL.
- Assay buffer 50 mM NaH 2 P0 4 , pH 6.8, 1 mM MgS04, 0.5 mM ThDP
- 2 ⁇ , of 1 ⁇ IPDC was added and generation of NADH was monitored at 340 nm.
- Kinetic parameters (k cat and K ) were determined by fitting initial rate data to the
- Protein name putative decarboxylase [Salmonella bongori NCTC 12419]
- Protein name putative decarboxylase [Salmonella enterica subsp. enterica serovar Typhi str. E98-0664]
- Protein name hypothetical protein SARI 00479 [Salmonella enterica subsp. arizonae serovar 62:z4,z23: ⁇ str. RSK2980]
- Protein name decarboxylase [Salmonella enterica subsp. enterica serovar Paratyphi A str. ATCC 9150]
- Protein name indole-3-pyruvate decarboxylase [Salmonella enterica subsp. enterica serovar Javiana str. GAJVIM04042433]
- Protein name decarboxylase [Salmonella enterica subsp. enterica serovar Typhi str. CT18]
- Protein name indole-3-pyruvate decarboxylase [Salmonella enterica subsp. enterica serovar Montevideo str. 315996572]
- Protein name putative thiamine pyrophosphate enzyme [Salmonella enterica subsp. enterica serovar Choleraesuis str. SC-B67]
- Protein name decarboxylase [Salmonella enterica subsp. enterica serovar Gallinarum str. 287/91]
- Protein name decarboxylase [Salmonella enterica subsp. enterica serovar Paratyphi C strain RKS4594]
- Protein name putative decarboxylase [Salmonella enterica subsp. enterica serovar Typhimurium str. SL1344]
- SeqID YP_001586815.1 GL161612850
- Protein name hypothetical protein SPAB 00555 [Salmonella enterica subsp. enterica serovar Paratyphi B str. SPB7]
- SeqID YP_002945800.1 GL239816890
- Protein name Aldehyde Dehydrogenase [Burkholderia sp. CCGE1002]
- SeqID YP_003907074.1 GL307729850
- Protein name Succinate-semialdehyde dehydrogenase (NAD(P)+) [Burkholderia cenocepacia PC184]
- Protein name NADP-dependent succinate-semialdehyde dehydrogenase [Burkholderia sp. TJI49]
- SeqID YP_002234153.1 GL206563390
- Protein name putative aldehyde dehydrogenase [Burkholderia cenocepacia J2315]
- Protein name succinate-semialdehyde dehydrogenase (NAD(P)(+)) [Burkholderia ambifaria AMMD] 1 manvtytdtq llidgewvda asgktidvvn patgkaigkv ahagiadldr alaaaqrgfe
- Protein name Aldehyde dehydrogenase, ALD6[Saccharomyces cerevisiae]
- Protein name Aldehyde dehydrogenase, ALD2 [Saccharomyces cerevisiae]
- Protein name Aldehyde dehydrogenase, ALD3 [Saccharomyces cerevisiae]
- 241 isftgstkvg gsvleasgqs nlkditlecg gkspalvfed adldkaiewv angiffnsgq 301 xctansrvyv qssxydkfve kfketakkew dvagkfdpfd ekcivgpvis stqydriksy
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG11201407375XA SG11201407375XA (en) | 2012-05-11 | 2013-03-13 | Biosynthetic pathways, recombinant cells, and methods |
US14/399,681 US20150132813A1 (en) | 2012-05-11 | 2013-03-13 | Biosynthetic pathways, recombinant cells, and methods |
KR1020147034378A KR20150014952A (en) | 2012-05-11 | 2013-03-13 | Biosynthetic pathways, recombinant cells, and methods |
CN201380035331.2A CN104520426A (en) | 2012-05-11 | 2013-03-13 | Biosynthetic pathways, recombinant cells, and methods |
JP2015511449A JP2015515866A (en) | 2012-05-11 | 2013-03-13 | Biosynthetic pathways, recombinant cells and methods |
AU2013260096A AU2013260096A1 (en) | 2012-05-11 | 2013-03-13 | Biosynthetic pathways, recombinant cells, and methods |
EP13715031.4A EP2847325A1 (en) | 2012-05-11 | 2013-03-13 | Biosynthetic pathways, recombinant cells, and methods |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261645900P | 2012-05-11 | 2012-05-11 | |
US61/645,900 | 2012-05-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013169350A1 true WO2013169350A1 (en) | 2013-11-14 |
Family
ID=48050901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/030719 WO2013169350A1 (en) | 2012-05-11 | 2013-03-13 | Biosynthetic pathways, recombinant cells, and methods |
Country Status (8)
Country | Link |
---|---|
US (1) | US20150132813A1 (en) |
EP (1) | EP2847325A1 (en) |
JP (1) | JP2015515866A (en) |
KR (1) | KR20150014952A (en) |
CN (1) | CN104520426A (en) |
AU (1) | AU2013260096A1 (en) |
SG (1) | SG11201407375XA (en) |
WO (1) | WO2013169350A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021060337A1 (en) * | 2019-09-25 | 2021-04-01 | Ajinomoto Co., Inc. | Method for producing 2-methyl-butyric acid by bacterial fermentation |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110331173B (en) * | 2019-07-29 | 2020-07-17 | 湖北大学 | Application of phenylpyruvic acid decarboxylase mutant M538A in production of phenethyl alcohol through biological fermentation |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998004715A1 (en) * | 1996-07-30 | 1998-02-05 | Archer-Daniels-Midland Company | Novel strains of escherichia coli, methods of preparing the same and use thereof in fermentation processes for l-threonine production |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009000046A (en) * | 2007-06-21 | 2009-01-08 | Hitachi Zosen Corp | Gene encoding enzyme involved in mevalonic acid pathway of eucommia ulmoides oliver |
-
2013
- 2013-03-13 SG SG11201407375XA patent/SG11201407375XA/en unknown
- 2013-03-13 KR KR1020147034378A patent/KR20150014952A/en not_active Application Discontinuation
- 2013-03-13 AU AU2013260096A patent/AU2013260096A1/en not_active Abandoned
- 2013-03-13 EP EP13715031.4A patent/EP2847325A1/en not_active Withdrawn
- 2013-03-13 CN CN201380035331.2A patent/CN104520426A/en active Pending
- 2013-03-13 WO PCT/US2013/030719 patent/WO2013169350A1/en active Application Filing
- 2013-03-13 JP JP2015511449A patent/JP2015515866A/en active Pending
- 2013-03-13 US US14/399,681 patent/US20150132813A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998004715A1 (en) * | 1996-07-30 | 1998-02-05 | Archer-Daniels-Midland Company | Novel strains of escherichia coli, methods of preparing the same and use thereof in fermentation processes for l-threonine production |
Non-Patent Citations (14)
Title |
---|
"Dow. Product Safety Assessment: Isopentanoic Acid", 2008, THE DOW CHEMICAL COMPANY |
BABA ET AL., MOL SYST BIOL, vol. 2, 2006 |
BARTSCH ET AL., J BACTERIOL, vol. 172, 1990, pages 7035 - 7042 |
DE LA PLAZA ET AL., FEMS MICROBIOL LETT, vol. 238, 2004, pages 367 - 374 |
GRUEZ ET AL., J MOL BIOL, vol. 343, 2004, pages 29 - 41 |
HO; WEINER, J BACTERIOL, vol. 187, 2005, pages 1067 - 1073 |
JO ET AL., APPL MICROBIOL BIOTECHNOL, vol. 81, 2008, pages 51 - 60 |
KECHUN ZHANG ET AL: "Expanding metabolism for total biosynthesis of the nonnatural amino acid L-homoalanine", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 107, no. 140, 1 March 2010 (2010-03-01), pages 6234 - 6239, XP008161919, ISSN: 0027-8424, [retrieved on 20100323], DOI: 10.1073/PNAS.0912903107 * |
LANGE ET AL., ANGEW CHEM INT EDIT, vol. 49, 2010, pages 4479 - 4483 |
MARTIN C H ET AL: "High-titer production of monomeric hydroxyvalerates from levulinic acid in Pseudomonas putida", JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 139, no. 1, 1 January 2009 (2009-01-01), pages 61 - 67, XP025796274, ISSN: 0168-1656, [retrieved on 20080925], DOI: 10.1016/J.JBIOTEC.2008.09.002 * |
RODRIGUEZ-ZAVALA ET AL., PROTEIN SCI, vol. 15, 2006, pages 1387 - 1396 |
XIONG ET AL., SCI REP, 2012, pages 2 |
ZHANG ET AL., CHEMSUSCHEM, vol. 4, 2011, pages 1068 - 1070 |
ZHANG ET AL., PROC NATL ACAD SCI USA, vol. 107, 2010, pages 6234 - 6239 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021060337A1 (en) * | 2019-09-25 | 2021-04-01 | Ajinomoto Co., Inc. | Method for producing 2-methyl-butyric acid by bacterial fermentation |
Also Published As
Publication number | Publication date |
---|---|
KR20150014952A (en) | 2015-02-09 |
JP2015515866A (en) | 2015-06-04 |
US20150132813A1 (en) | 2015-05-14 |
SG11201407375XA (en) | 2014-12-30 |
CN104520426A (en) | 2015-04-15 |
AU2013260096A1 (en) | 2014-11-27 |
EP2847325A1 (en) | 2015-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2429295C2 (en) | Enzymatic production of 1-butanol | |
EP2142656B1 (en) | Method for the production of 1-butanol | |
JP5276986B2 (en) | Fermentative production of four-carbon alcohol | |
EP2678432B1 (en) | Recombinant microorganisms and uses therefor | |
US20150072399A1 (en) | Methods, Systems And Compositions Related To Reduction Of Conversions Of Microbially Produced 3-Hydroxypropionic Acid (3-HP) To Aldehyde Metabolites | |
US20140065697A1 (en) | Cells and methods for producing isobutyric acid | |
US20090111154A1 (en) | Butanol production by recombinant microorganisms | |
US20100221800A1 (en) | Microorganism engineered to produce isopropanol | |
JP2011522541A (en) | Deletion mutants for producing isobutanol | |
US9410130B2 (en) | Recombinant microorganisms and uses therefor | |
BRPI0809771A2 (en) | METHOD FOR ISOBUTHANOL PRODUCTION | |
US20160024532A1 (en) | Atp driven direct photosynthetic production of fuels and chemicals | |
AU2013267968A1 (en) | Biosynthetic pathways, recombinant cells, and methods | |
WO2012135731A2 (en) | Alcohol production from recombinant microorganisms | |
JP2017534268A (en) | Modified microorganisms and methods for the production of useful products | |
Dhande et al. | Production of C5 carboxylic acids in engineered Escherichia coli | |
US20150132813A1 (en) | Biosynthetic pathways, recombinant cells, and methods | |
US20140329275A1 (en) | Biocatalysis cells and methods | |
US20160138049A1 (en) | OXYGEN-TOLERANT CoA-ACETYLATING ALDEHYDE DEHYDROGENASE CONTAINING PATHWAY FOR BIOFUEL PRODUCTION | |
RU2375451C1 (en) | RECOMBINANT PLASMID DNA, CONTAINING GENES OF BUTANOL SYNTHESIS FROM Clostridium acetobutylicum (VERSIONS), RECOMBINANT STRAIN Lactobacillus brevis - PRODUCER OF N-BUTANOL (VERSIONS) AND METHOD FOR MICROBIOLOGICAL SYNTHESIS OF N-BUTANOL | |
MX2008004086A (en) | Fermentive production of four carbon alcohols |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13715031 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14399681 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2015511449 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2013260096 Country of ref document: AU Date of ref document: 20130313 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20147034378 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2013715031 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013715031 Country of ref document: EP |